Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride, the active ingredient in Mydriasert, is an alpha‑adrenergic agonist presented as an ophthalmic solution for ocular (topical) use. Together with Tropicamide, it dilates the pupil and induces cycloplegia for diagnostic and surgical eye procedures.\n\nGNH India supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mydriasert, a combination mydriatic/cycloplegic ophthalmic solution, acts on the iris muscles to produce pupil dilation.\n\nDiagnostic eye examinations: provides rapid pupil dilation to facilitate fundus evaluation.\nIntraocular surgery: creates adequate mydriasis for safe surgical access.\nCycloplegic testing: temporarily paralyzes accommodation for accurate refractive measurements.

Adverse reactions may occur following ocular administration of Mydriasert.\n\nCommon Side Effects:\n- Transient ocular burning or stinging\n- Mild conjunctival hyperemia\n- Temporary blurred vision\n- Increased intraocular pressure in susceptible patients\n\nSerious or Rare Side Effects:\n- Acute angle‑closure glaucoma\n- Severe allergic reaction (anaphylaxis)\n- Systemic cardiovascular effects such as hypertension or tachycardia

Use Mydriasert only under professional supervision and consider patient‑specific factors.\n\nAssess intraocular pressure before use: avoid in patients with narrow‑angle glaucoma.\nScreen for hypersensitivity: discontinue if allergic reaction occurs.\nUse lowest effective dose: limit exposure to reduce systemic absorption.\nAvoid concurrent use with other mydriatics: may cause excessive dilation.\nMonitor in pediatric patients: increased sensitivity to anticholinergic effects.\nStore at room temperature: keep in original container, protect from light and moisture.

Mydriasert may interact with other systemic or ocular agents; review patient medication lists.\n\nMajor Interactions (Avoid):\n- Systemic sympathomimetics (e.g., oral phenylephrine): additive hypertensive effects.\n- Other anticholinergic ophthalmic agents: risk of excessive cycloplegia.\n- Monoamine oxidase inhibitors: potential for hypertensive crisis.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: may blunt intraocular pressure reduction.\n- Topical anesthetics: may increase corneal absorption of active ingredients.\n- Systemic antihypertensives: monitor blood pressure during use.